The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia | Zendy

Sinem Nihal Esatoğlu | Zendy; Dilek Keskin | Zendy; Ahmet Emre Eşkazan | Zendy; Tuğrul Elverdi | Zendy; Ayşe Salihoğlu | Zendy; Muhlis Cem Ar | Zendy; Şeniz Öngören | Zendy; Zafer Başlar | Zendy; Yıldız Aydin | Zendy; Hafize Uzun | Zendy; Teoman Soysal | Zendy

Open Access

The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia

Author(s) -

Sinem Nihal Esatoğlu,

Dilek Keskin,

Ahmet Emre Eşkazan,

Tuğrul Elverdi,

Ayşe Salihoğlu,

Muhlis Cem Ar,

Şeniz Öngören,

Zafer Başlar,

Yıldız Aydin,

Hafize Uzun,

Teoman Soysal

Publication year - 2020

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-2004-282

Subject(s) - medicine , chemotherapy , chronic lymphocytic leukemia , gastroenterology , confidence interval , leukemia , oncology , immunology

A proliferation-inducing ligand (APRIL) has been investigated as a prognostic marker in chronic lymphocytic leukemia (CLL) patients. However, there is no cut-off level for serum APRIL (sAPRIL) levels that predict time to treatment in CLL patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore